TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07218380: FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07218380 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07218380 Rescue Dossier →